Bryan Morton joined EW in 2017 as an Operating Partner after a ten-year relationship with EW as CEO and Chairman of two EW growth equity portfolio companies, EUSA Pharma “I” and EUSA Pharma “II”.
Mr. Morton is a five-time company founder, CEO and Chairman of specialty pharmaceutical companies. He founded EW portfolio company EUSA Pharma “I” in 2006 as a transatlantic specialty pharmaceutical company focused on oncology and critical care and served as the President and CEO of EUSA “I” until the sale of the company to Jazz Pharmaceuticals in 2012.
In 2015 Mr. Morton and Fund 1 re-acquired certain EUSA “I” assets from Jazz Pharmaceuticals in order to create a new oncology specialty pharmaceutical company. Mr. Morton also acquired the name EUSA Pharma from Jazz Pharmaceuticals and helped build EUSA Pharma “II” into a Fund 1 portfolio company, which was acquired by Recordati in March 2022.
Prior to founding the original EUSA Pharma, Mr. Morton started Zeneus Pharma through the purchase of Elan’s European business and served as the company’s CEO. Zeneus was acquired two years later by Cephalon. Mr. Morton also founded two biopharmaceutical companies, Izana Bio and Akaza Bio. Izana was recently sold and Akaza is developing a drug candidate in Acute Liver Disease based on a license of a TLR4 drug from Takeda.
Previously, Mr. Morton held several senior executive positions in the United States, the UK, Belgium and Australia with Merck & Co Inc. and Bristol Myers Squibb.
Mr. Morton holds a Master of Business Administration degree from Durham University and is an Honorary Professor at Durham University Business School. Mr. Morton also holds a Bachelor of Science degree in Pharmacology from Aberdeen University in Scotland and is a graduate of the INSEAD European Management Programme.
Mr. Morton was honored in 2016 by Her Majesty the Queen and was awarded a CBE (Commander of the Most Excellent Order of the British Empire) for services to the Healthcare Industry.